tirzepatide product Compounded Program: Results, Timeline & Comparison Tirzepatide Weight Loss Injections |

Treatment of cardiac transthyretin amyloidosis: an update

The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect

6 It would not be surprising to see a repeat of the VinFuture scenario, where prize committees take the initiative to expand the list of laureates out of awareness of past oversights

However, an important factor is what happens after stopping the medication